King's College London

Research portal

Adjuvants in Allergy: State of the Art

Research output: Contribution to journalReview articlepeer-review

Saima Alam, Joanna Lukawska, Christopher Corrigan

Original languageEnglish
Pages (from-to)39-47
Number of pages9
JournalCurrent Treatment Options in Allergy
Issue number1
PublishedMar 2014

King's Authors


Allergen-specific immunotherapy is administered through subcutaneous or sublingual routes to induce immunological tolerance to allergens. It is the only management option available for treating IgE-mediated allergy to seasonal and perennial allergens by disease modification, resulting in long-term remission. In the last few decades, research into the long-term efficacy and safety profiles of vaccines has led to the increased use of adjuvants in allergen immunotherapy. Through activation of innate immune pathways, adjuvants have been shown to improve the efficacy and safety profiles of allergen vaccines. This paper provides an overview of adjuvants, both in clinical and preclinical settings, currently in use for allergen immunotherapy.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454